OWPC One World Products Inc (QB)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * RABEN BRUCE I	2. Issuer Name and Ticker or Trading Symbol One World Pharma, Inc. [ OWPC ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Interim CFO
(Last)          (First)          (Middle) 100 WILSHIRE BLVD., # 700	3. Date of Earliest Transaction (MM/DD/YYYY) 12/31/2020
(Street) SANTA MONICA, CA 90401 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/31/2020		A		750000	A	$0	875000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$0.56	12/31/2020		D			350000	(1)	5/31/2030	Common Stock	350000	$0	0	D
Stock Option (Right to Buy)	$0.50	12/31/2020		D			125000	2/8/2019	2/8/2022	Common Stock	125000	$0	0	D
Stock Option (Right to buy)	$0.13	1/1/2021		A		475000		(2)	12/31/2030	Common Stock	475000	$0	475000	D

Explanation of Responses:
(1)	The option vested immediately as to 116,667 shares upon issuance, and as to the remaining shares in eight equal quarterly installments on the first day of each calendar quarter, beginning September 1, 2020.
(2)	The option vests as to 25% of the shares subject to the option on each of March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
RABEN BRUCE I 100 WILSHIRE BLVD., # 700 SANTA MONICA, CA 90401	X		Interim CFO

Signatures
/s/ Bruce I. Raben		1/4/2021
**Signature of Reporting Person		Date